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Abstract
Background: Cerebral venous thrombosis (CVT) is a disease with a wide spectrum of symptoms and severity. In
this study we analysed the predictive value of clinical signs and symptoms and the contribution of D-dimer
measurements for diagnosis.
Methods: We evaluated consecutive patients admitted with suspected CVT receiving non-invasive imaging.
Symptoms and symptom combination as well as D-dimer levels were evaluated regarding their diagnostic value.
Results: 239 patients were included in this study, 170 (71%) were females. In 39 patients (16%) a CVT was found.
For identifying a CVT patients underwent either a venous CT-angiography or MR-angiography or both. No
combination of symptoms either alone or together with the D-dimer measurements had a sensitivity and positive
predictive value as well as negative predictive value and specificity high enough to serve as red flag. D-dimer
testing produced rates of 9% false positive and of 24% false negative results. For D-dimer values a Receiver
Operating Characteristic curve (ROC) and the area under the curve (AUC = 0.921; CI: 0.864 - 0.977) were calculated.
An increase of sensitivity above 0.9 results in a relevant decrease in specificity; a sensitivity of 0.9 matches a
specificity value of 0.9. This corresponds to a D-dimer cut-off level of 0.16 μg/ml.
Conclusion: Imaging as performed by venous CT-angiography or MR-angiography has a 1 to 2 in 10 chance to
detect CVT when typical symptoms are present. D-dimer measurements are of limited clinical value because of
false positive and negative results.
Background
Patients with cerebral venous thrombosis (CVT) present
with a remarkably wide spectrum of signs and symptoms.
Most common are headaches (> 80%), seizures (approxi-
mately 40%), hemiparesis (approximately 40%), altered
consciousness (15-20%), and papilledema (20-30%) [1-3].
The relative frequency in cohort of patients with increas-
ing headache without previous headaches history or
headaches in combination with neurological deficits or
seizures has been reported at approximately 10%, but has
not yet been confirmed by other studies [4].
The non-specificity of most of the presenting symp-
toms of CVT poses major problems in an emergency
room setting, because i.e. it might be difficult to screen
every patient with headaches for CVT by magnetic
resonance imaging (MRI). Current data on the sympto-
matology of CVT give no information on the predictive
value of specific modes of presentation or their combi-
nation. Elevated D-dimers have been reported to have a
high diagnostic sensitivity and specificity [4]. Yet, other
investigations found considerable rates of false positive
and negative results [5-10].
In this study we aimed therefore to investigate the rela-
tive frequency of CVT in a cohort of patients with clinical
symptoms suggestive of this disease. Further the predictive
value of different clinical signs and symptoms in patients
suspected to suffer of CVT should be determined.
Methods
Patients
In a retrospective study we analyzed all consecutive
patients admitted to our neurological department between
August 2002 and November 2007 who were initially sus-
pected of suffering of CVT and underwent either magnetic
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graphy (MRA) or venous computed tomography angiogra-
phy (CTA). Routinely T1-, T2-weighted images, FLAIR,
DWI, and T2* sequences were carried out. Diagnostic cri-
teria followed usual guidelines [11]. Readers were not
blinded to the patient’s clinical situation. Patients were
initially identified based on an imaging data base. Symp-
toms which lead to the suspicion of an underlying CVT
were identified retrospectively by reviewing case files. The
medical history and neurological examination were ana-
lyzed regarding the findings which led to the suspicion of
CVT. Papilledema was assessed clinically by ophthalmo-
scopy. All patients with suspected papilledema were exam-
ined by an ophthalmologist. Headaches were recorded as
acute when onset was ≤ 24 hours, or as subacute when
they lasted > 1 day. Further, thrombus localization and the
presence of venous infarcts were registered. D-dimers in
serum were measured using a turbidimetric method with
a normal reference range below 0.19 μg/ml and were
recorded when performed on the day of admission. The
study protocol was reviewed and approved by the local
ethical committee of the Justus Liebig University of
Giessen.
Statistical Evaluation
For defined parameters the positive predictive value
(PPV), negative predictive value (NPV), sensitivity and
specificity were calculated based on cross-tables. To
compare nonparametric data the Mann-Whitney U-test
was applied. For frequency data a c
2-test or when
appropriate Fisher’s exact test were used.
For the determination of different cut-off points for D-
dimer levels indicating a CVT the true positive rate (sen-
sitivity) in function of the false positive rate (1-specificity)
was plotted to a Receiver Operating Characteristic (ROC)
curve. For the estimation of the discriminatory accuracy
of D-dimer measurement in indicating a CVT the area
under the ROC curve (AUC) was calculated.
For identifying specific combinations of symptoms
indicating a CVT, clusters were built applying the
Schwarz’s Bayesian criterion with logarithmic-likelihood
distance measure.
Results
In total, we identified 239 patients (170 [71%] females,
69 [29%] males) who received MRI and venous MRA
(188 patients, 78.7%) or venous CTA (61 patients,
25.5%) to rule out CVT; in 10 patients both procedures
were performed. None had conventional angiography.
Important demographic data are summarized in Table 1.
We found CVT in 16.3% of patients. Presenting symp-
toms and thrombus location are listed in Table 1. High-
est PPV was observed for the combinations of headaches
plus seizures (0.57), headaches plus papilledema (0.57)
and focal neurological deficit plus papilledema (1.0)
(Table 2, Figures 1 and 2).
In 98 patients D-dimer levels were determined within 6
hours after admission. An increased D-dimer value was
significantly more frequent in patients with CVT (p <
0.01); comparing absolute ranges higher values for D-
dimers were detected in patients with CVT (median 0.21
μg/ml versus 0.07 μg/ml). D-dimer measurements primar-
ily increased PPV and specificity (Figures 1 and 2). We
found rates of 9% false positive and of 24% false negative
results. For D-dimer values a ROC curve and the area
under the curve (AUC = 0.921; CI: 0.864 - 0.977) were cal-
culated (Figure 3). An increase of sensitivity above 0.9
results in a relevant decrease in specificity; a sensitivity of
0.9 matches a specificity value of 0.9 (Figure 3). The 90%
Table 1 Demographic data
CVT
n=3 9
(16.3%)
No CVT
n = 200
(83.7%)
p
Age (y) 43.9 42.5 0.73
Sex 0.93
Males 12 (31%) 57 (29%)
Females 27 (69%) 143 (71%)
Imaging
MRI/MRA 30 (77%) 158 (79%) 0.94
CTA 12 (31%) 49 (24%) 0.62
Symptoms/History
Headaches 27 (69%) 145 (73%) 0.83
- acute (≤ 1day) 2 (5%) 34 (17%) 0.09
- subacte (> 1 day) 25 (64%) 111 (56%) 0.41
- unilateral 7 (18%) 30 (15%) 0.63
Seizure (focal or
generalized)
11 (28%) 19 (10%) 0.003
Focal neurological deficit 17 (44%) 68 (34%) 0.33
Papilledema 4 (10%) 4 (4%) 0.15
Disturbed consciousness 0 (0%) 10 (5%) 0.32
Pregnancy* 3 (11%) 12 (8%) 0.43
Previous venous
thrombosis
5 (13%) 24 (12%) 0.90
Oral contraceptives* 6 (22%) 29 (20%) 0.49
D-Dimer measurement 29 (74%) 69 (35%) 0.001
Increased
§ 22 (76%) 6 (9%) 0.001
Absolute values (μg/ml),
median (range)
0.21 (0.09 - 2.51) 0.07 (0.01 - 3.1) 0.001
Thrombus location Not applicable
Superior sagittal sinus 14 (36%)
Transverse sinus 24 (83%)
Sigmoid sinus 6 (21%)
Internal jugular vein 3 (10%)
Straight sinus 10 (34%)
Cortical veins 1 (3%)
* limited to females.
§ limited to patients with D-dimer measurements, reference range below
0.19 μg/ml.
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off level (0.16 μg/ml) for the identification of patients with
CVT with a sensitivity of 90% and a specificity of 90%.
For identifying specific combinations of symptoms
potentially indicating a CVT, 2 clusters were calculated.
Considering redundancies the following parameters were
selected: gender, seizure, focal neurological deficit, head-
ache, papilledema, altered consciousness and previous
DVT or PE. The quality of the clusters was slightly above
average as indicated by the silhouette- cohesion- and
separation coefficient (k = 0.4). The distribution of para-
meters among the 2 clusters is summarized in Table 3.
Cluster 1 includes the majority of the patients with CVT
(32/133 versus 7/106; p < 0.001); a sensitivity of 0.82 and a
specificity of 0.50 respectively was calculated, respectively.
Discussion
The symptomatology of this patient cohort complies
well with prospective CVT patients collectives [1,4]. We
found an astonishingly high rate of CVT of approxi-
mately 16% in our patients which also corroborates
results of a prospective study aimed at investigating the
diagnostic value of D-dimers [4] which found a rate of
approximately 10%.
No symptom combination reached a high enough PPV
and sensitivity as well as NPV and specificity to serve as a
red flag although headaches plus seizures, headaches plus
papilledema, and focal neurological deficit plus papille-
dema (Table 2, Figures 1 and 2) are suggestive of CVT.
When typical symptoms are present there is a 1 to 2 in 10
chance to detect CVT by appropriate non-invasive
Table 2 Positive (PPV) and negative predictive value (NPV), sensitivity (Sens), specificity (Spec), and effectivity (Effect)
of symptoms and symptom combinations in diagnosis of cerebral venous thrombosis (CVT)
Parameter CVT vs. no CVT PPV NPV Sens Spec Effect
Headaches (any form) 27/39 vs. 145/200 0.17 0.82 0.69 0.28 0.34
- plus seizure (focal or generalized) 4/39 vs. 3/200 0.57 0.85 0.10 0.99 0.84
- plus focal neurological deficit 12/39 vs. 39/200 0.23 0.86 0.31 0.81 0.72
- plus previous history of DVT or PE 5/39 vs. 24/200 0.33 0.84 0.07 0.97 0.82
- plus papilledema 4/39 vs. 3/200 0.57 0.85 0.10 0.99 0.84
- plus altered consciousness 0/39 vs. 1/200 0.00 0.84 0.00 0.99 0.83
- plus oral contraceptives* 6/27 vs. 26/143 0.19 0.85 0.22 0.82 0.72
- plus increased D-dimers§ 14/29 vs. 7/69 0.67 0.81 0.48 0.89 0.78
Seizures (focal or generalized) 11/39 vs. 19/200 0.37 0.86 0.28 0.91 0.80
- plus focal neurological deficit 2/39 vs. 3/200 0.40 0.84 0.05 0.99 0.83
- plus previous history of DVT or PE 1/39 vs. 1/200 0.50 0.84 0.03 0.99 0.84
- plus papilledema 0/39 vs. 0/200 - - - - -
- plus altered consciousness 0/39 vs. 1/200 0.00 0.84 0.00 0.99 0.83
- plus oral contraceptives* 1/27 vs. 1/143 0.03 0.96 0.17 0.80 0.78
- plus increased D-dimers§ 8/29 vs. 1/69 0.89 0.76 0.28 0.98 0.78
Focal neurological deficit 17/39 vs. 68/200 0.20 0.86 0.44 0.66 0.62
- plus previous history of DVT or PE 1/39 vs. 6/200 0.14 0.83 0.02 0.97 0.81
- plus papilledema 2/39 vs. 0/200 1.00 0.84 0.05 1.00 0.85
- plus altered consciousness 0/39 vs. 2/200 0.00 0.84 0.00 0.99 0.83
- plus oral contraceptives* 3/27 vs. 5/143 0.38 0.85 0.11 0.97 0.83
- plus increased D-dimers§ 11/29 vs. 1/69 0.92 0.79 0.38 0.98 0.81
Altered consciousness 0/39 vs. 10/200 0.00 0.83 0.00 0.95 0.79
- plus previous history of DVT or PE 0/39 vs. 1/200 0.00 0.84 0.00 0.99 0.83
- plus papilledema 0/39 vs. 0/200 - - - - -
- plus oral contraceptives* 0/39 vs. 1/200 0.00 0.84 0.00 0.99 0.83
- plus increased D-dimers§ 0/29 vs. 1/69 0.00 0.70 0.00 0.99 0.69
Papilledema 4/39 vs. 7/200 0.36 0.85 0.10 0.97 0.82
- plus previous history of DVT or PE 1/39 vs. 1/200 0.50 0.84 0.03 0.99 0.84
- plus oral contraceptives* 1/39 vs. 1/200 0.50 0.84 0.03 0.99 0.84
- plus increased D-dimers
§ 3/29 vs. 1/69 0.75 0.72 0.10 0.99 0.72
Increased D-dimers§ 22/29 vs. 6/69 0.79 0.90 0.76 0.91 0.87
DVT: deep vein thrombosis of the legs
PE: pulmonary embolism
*limited to females
§limited to patients with D-dimer measurements
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nation of symptoms with acceptable sensitivity and specifi-
city in indicating a CVT.
In our cohort D-dimer testing produced rates of 9%
false positive and of 24% false negative results which
sheds serious doubts on their usefulness in a clinical set-
ting. In cohorts with typical symptomatology they may
primarily increase specificity. In contrast, the ROC analy-
sis revealed a sensitivity of 90% and a specificity of 90%
when considering a D-dimer cut-off value of 0.16 μg/ml;
the AUC indicates a favorable discriminatory accuracy
for D-dimer in indicating a CVT in general. However,
considering normal ranges established in our laboratory
(< 0.19 μg/ml) a value of 0.16 μg/ml might be regarded as
normal. On the other hand, normal ranges for D-dimer
values are derived considering venous embolic events
such as pulmonary embolism or venous thrombosis of
the pelvic and leg veins. Therefore a D-dimer measure-
ment might have a beneficial impact, nonetheless the
determined cut-of value of 0.16 μg/ml has to be regarded
a pivotal finding, which requires verification.
A limitation of this investigation is its retrospective
design. Missing patients are unlikely because the data
base used is also the basis for hospital payment. In all
cases the treating neurologist already considered CVT
as potential differential diagnosis which may introduce a
selection bias. Presumably this explains the relatively
Figure 1 Positive and negative predictive values for main
symptoms with and without D-dimer measurements.
Figure 2 Sensitivity and specificity for main symptoms with
and without D-dimer measurements.
Figure 3 ROC curve for diagnosing a cerebral vein thrombosis
by D-dimer measurement.
Table 3 Distribution of parameters among clusters
Cluster 1
n = 133
(55.6%)
Cluster 2
n = 106
(44.4%)
p
Sex 0.06
Males 45 (34%) 24 (23%)
Females 88 (66%) 82 (77%)
Symptoms
Headaches 66 (50%) 106 (100%) < 0.001
Seizure (focal or
generalized)
30 (23%) 0 (0%) < 0.001
Focal neurological
deficit
85 (64%) 0 (0%) < 0.001
Papilledema 11 (8%) 0 (0%) 0.001
Disturbed
consciousness
10 (8%) 0 (0%) 0.003
Previous history of DVT
or PE
17 (13%) 0 (0%) < 0.001
CVT 32 (24%) 7 (7%) < 0.001
DVT: deep vein thrombosis of the legs
PE: pulmonary embolism
CVT: cerebral vein thrombosis.
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higher rate of D-dimer measurements in CVT patients
compared with non-CVT patients is most likely due to
the fact, that treating neurologists were not blinded to
the imaging results and diagnosis.
Conclusions
Even considering limitations the results of this investiga-
tion clearly emphasizes that when typical symptoms are
present a rate of 10 to 20% of CVT can be suspected.
CVT is not a rare condition. There is no typical red flag
symptomatology. The usefulness of D-dimer measure-
ments is limited because measurements produce false
positive and negative results.
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